Saturday 17 October 2026
Export RVMD’s income statement to Excel — free account
Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022. In the quarter to June 2026, EPS fell 133.6%, free cash flow fell 70.0% and total debt rose 322.7%, each against the same quarter a year earlier.
177.96
11.30
−5.97%
Follow RVMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.86 | 6.97 | 6.59 | 11.12 | |
Current Ratio |
8.05 | 7.14 | 6.80 | 11.38 | |
Net Debt/EBITDA |
5.29 | 4.86 | 3.67 | 5.75 | |
Debt/Assets |
11.39% | 11.40% | 12.45% | 23.96% | |
Debt/Equity |
0.16 | 0.16 | 0.19 | 0.40 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.75 | 0.78 | 0.60 | |
Capex/Depreciation |
2.43 | (13.01) | (1.17) | (13.69) | |
Interest Coverage |
(27.59) | (30.30) | (36.50) | (21.24) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.02 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.10) | (1.44) | (1.79) | (1.84) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(1.11) | (1.45) | (1.80) | (1.85) | |
Cash per Share |
10.21 | 10.65 | 9.63 | 18.67 | |
Shareholders Equity per Share |
8.44 | 8.58 | 7.57 | 12.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.44 | 8.58 | 7.57 | 12.36 | |
Free Cash Flow |
(210.66) | (276.16) | (355.70) | (389.60) | |
Working Capital |
1,731.87 | 1,784.61 | 1,678.31 | 3,674.28 | |
Capital Expenditures |
(3.35) | (1.92) | (1.54) | (2.29) | |
Net Current Asset Value |
1,322.47 | 1,351.83 | 1,214.09 | 2,311.31 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
49.65 | 59.52 | 64.02 | 72.59 | |
Average Assets |
2,007.46 | 2,456.40 | 2,309.55 | 3,376.42 | |
Average Common Equity |
1,581.60 | 1,948.25 | 1,789.03 | 2,235.80 |
Columns are period end dates